ClinicalTrials.gg
Not yet recruitingNCT07621146NET-COMPAREUpdated Oct 6, 2026

A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies

An observational study in Neuroendocrine Tumors, NET, Pheochromocytoma/Paraganglioma and SSTR-expressing Tumors, sponsored by British Columbia Cancer Agency. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Primary conditionPheochromocytomaRegistry: Neuroendocrine TumorsReclassifiedWhy we changed it
Registry
Neuroendocrine Tumors — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pheochromocytoma
Why
  1. The study's listed conditions name Pheochromocytoma, a narrower term within Neuroendocrine Tumors.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by British Columbia Cancer Agency · Observational

How we know

Updated Oct 6, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Study summary

Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of molecules called somatostatin receptors (SSTR) which requires specific PET scan tracers to sufficiently capture on images. The current standard of care tracer at BC Cancer for SSTRs on NETs is 68Ga-DOTATATE. This project seeks to identify if 18F-AmBF3-TATE (a tracer that has established safety from phase 1 trial results), is comparable in disease detection, no. of lesions identified, image quality, safety and overall accuracy, to 68Ga-DOTATATE.

02

Conditions studied

  • Neuroendocrine Tumors, NET
  • Pheochromocytoma/Paraganglioma
  • SSTR-expressing Tumors
  • Medullary Thyroid Carcinoma

Browse trials for

03

In context

Pheochromocytoma Reclassified

158 studies on the registry are indexed under Pheochromocytoma; 57 are open to participants now.

This study's planned enrollment of 60 is below the median of 184 across 56 observational studies indexed under Pheochromocytoma.

Browse Pheochromocytoma studies →

Lead sponsor

British Columbia Cancer Agency is the lead sponsor of 153 studies on the registry; 33 are open to participants now.

Compared within Pheochromocytoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neuroendocrine Tumors. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

This will be a prospective, open-label trial in patients with suspected or proven SSTR positive tumors.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Patients referred for and meeting institutional criteria for a [68Ga]DOTATATE PET/CT for the investigation of a known or suspected neuroendocrine (BC Cancer criteria APPENDIX A).

Exclusion criteria

Exclusion Criteria:

  • Pregnant and breast-feeding patients.
  • Patients unwilling or unable to undergo a second PET/CT.
  • Patients exceeding the safe weight limit of the scanner (204.5 kg) or who cannot fit through the PET/CT bore (70cm diameter).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • PET/CT Diagnostic Imaging

    Each subject will have two PET/CT scans, one using 68Ga-DOTATATE and the other using 18F-AmBF3-TATE. The 18F-AmBF3-TATE radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada. 68Ga-DOTATATE is considered standard care and has been approved by Health Canada.

    Diagnostic Test: 68Ga-DOTATATE PET/CT · Diagnostic Test: 18F-AmBF3-TATE PET/CT

Interventions

  • Diagnostic test68Ga-DOTATATE PET/CT

    Each study participant will have an intravenous catheter inserted. The participant will receive a bolus intravenous dose of the standard of care tracer 68Ga-DOTATATE from an approved study supplier site. After a 60 minute uptake phase, the participant will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract. Participants are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired.

  • Diagnostic test18F-AmBF3-TATE PET/CT

    Each study participant will have an intravenous catheter inserted. The participant will receive a bolus intravenous dose of the investigational tracer 18F-AmBF3-TATE from an approved study supplier site. After a 60 minute uptake phase, the participant will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract. Participants are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired.

06

What researchers measure

Primary outcomes

  1. Number of lesions detected by [18F]AmBF3TATE compared to [68Ga]DOTATATE

    To assess the non-inferiority of \[18F\]AmBF3TATE compared to the standard-of-care \[68Ga\]DOTATATE

    Time frame: Periprocedural

Secondary outcomes

  1. Number of patients in whom one or more target lesions are detected by the core readers.

    Number of patients in whom \[18F\]AmBF3TATE and \[68Ga\]DOTATATE detects disease.

    Time frame: within 2 weeks of the scan

  2. Standard Uptake Values (SUV) for lesions detected

    To assess uptake values (SUV) for tumour lesions (SUVmax, SUVpeak, tumour to background ratio for liver, blood, kidney and lung, contrast and signal to noise ratio).

    Time frame: within 2 weeks of the scan

  3. CNR (contrast to noise ratio), TBR (tumor tissue to background tissue ratio), Tumor/blood; Tumor/Liver; Tumor/ kidney; tumor/lung, Likert scale for reader quality assessment

    To assess image quality using semi-quantitative (contrast-to-noise and tumour-to-background) and subjective indices

    Time frame: within 2 weeks of the scan

  4. Diagnostic confidence on a three-point scale (high, moderate and low), Fleiss' Kappa to measure inter-rater agreement

    To assess reader confidence and inter-rater agreement

    Time frame: within 2 weeks of the scan

  5. Frequency of adverse events (AE) and serious adverse events (SAE).

    To compare the safety of both tracers

    Time frame: Immediately post-scan

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Jun 2027, 7 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: start Sep 2026 → Nov 2026 and primary completion Mar 2027 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2026
First posted
Jun 2, 2026
StartEst.
Nov 30, 2026was Sep 2026
Primary completionEst.
Jun 2027was Mar 2027
CompletionEst.
Mar 2028
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 15, 2026→Nov 30, 2026
Oct 6, 2026
Primary completion
Mar 2027→Jun 2027
Oct 6, 2026
Enrollment
51→60
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Start date Sep 15, 2026→Nov 30, 2026
    Primary completion Mar 2027→Jun 2027
    Enrollment 51→60
    + 2 other changes: verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07621146
Responsible party
Sponsor
First posted
Jun 2, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Oct 6, 2026

Study contacts

Research Project Manager
Contact
MITclinicaltrials@bccancer.bc.ca
604-675-8000 ext. 7649
Administrative Research Manager
Contact
MITclinicaltrials@bccancer.bc.ca
604-877-6000 ext. 2818
Ian Alberts, MBBS MD PhD FEBNM
principal investigator · BC Cancer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion